Hennessy Advisors Inc. Buys 7,070 Shares of Amgen Inc. $AMGN

Key Points

• Hennessy Advisors increased its Amgen stake by 58.7% in the second quarter, purchasing 7,070 shares to hold 19,120 shares worth approximately $6.9 million. Institutional investors collectively own 76.5% of Amgen.
• Amgen reported quarterly earnings of $6.29 per share and revenue of $10.05 billion, exceeding analyst estimates, while revenue rose 9.5% year over year. The company maintained fiscal 2026 EPS guidance of $22.30–$23.50.
• Amgen declared a quarterly dividend of $2.52 per share, equivalent to an annualized $10.08 payout and a 2.3% yield. Despite strong operating results, analysts maintain a consensus “Hold” rating with an average price target of $380.43.

Hennessy Advisors Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 58.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,120 shares of the medical research company's stock after acquiring an additional 7,070 shares during the period. Hennessy Advisors Inc.'s holdings in Amgen were worth $6,924,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. Norges Bank bought a new position in shares of Amgen during the 4th quarter valued at about $2,164,162,000. Bank of America Corp DE purchased a new position in shares of Amgen during the second quarter valued at about $1,831,903,000. Capital World Investors increased its holdings in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company's stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company's stock worth $993,031,000 after buying an additional 2,514,254 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after buying an additional 2,261,544 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Amgen stock opened at $432.42 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The stock has a market cap of $233.78 billion, a price-to-earnings ratio of 26.88, a price-to-earnings-growth ratio of 3.12 and a beta of 0.41. The firm has a 50-day moving average of $388.64 and a two-hundred day moving average of $364.71. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the company posted $6.02 earnings per share. The company's quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts forecast that Amgen Inc. will post 22.97 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares of the company's stock, valued at $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire expands its potential market. Amgen and AstraZeneca reported that Tezspire met both co-primary and all key secondary endpoints in the Phase 3 CROSSING study for eosinophilic esophagitis (EoE). Improvements in tissue inflammation and swallowing symptoms were statistically significant, clinically meaningful and sustained through 52 weeks. EoE could become Tezspire’s third approved indication, adding a potentially significant growth opportunity beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 EoE Results
• Positive Sentiment: Recent financial performance remains supportive. Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Strong results and full-year guidance have helped keep the stock near its 52-week high and provide a favorable backdrop for pipeline news. Amgen Earnings and Guidance
• Neutral Sentiment: Additional pipeline updates offer limited near-term valuation impact. Amgen provided updates on a pediatric psoriasis study involving apremilast and began a Phase 1 trial of AMG 691 aimed at markets in Asia. These programs may support long-term growth, but both remain too early to materially affect current earnings expectations. Amgen Pediatric Psoriasis Study
• Negative Sentiment: Amgen ended its Crohn’s disease research partnership with TScan Therapeutics. Terminating the collaboration removes an external source of potential inflammatory bowel disease assets and may raise questions about the company’s strategy in this research area. The impact is likely limited near term because the program was still focused on target discovery. Amgen Ends Crohn’s Research Partnership

Analyst Upgrades and Downgrades

AMGN has been the topic of several research reports. UBS Group boosted their price target on shares of Amgen from $420.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Guggenheim increased their price target on shares of Amgen from $343.00 to $388.00 and gave the company a "neutral" rating in a report on Monday, August 10th. Freedom Capital upgraded Amgen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, May 7th. Sanford C. Bernstein boosted their price objective on Amgen from $335.00 to $345.00 and gave the stock a "market perform" rating in a research note on Thursday, August 6th. Finally, Daiwa Securities Group decreased their price objective on Amgen from $410.00 to $390.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $380.43.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source